Hematopoietic Stem Cell Transplantation Market Size, Business Experts, Future Bar, Top Players And Forecast 2023 to 2033

BySanket Badgujar
Market Research

The global Hematopoietic Stem Cell Transplantation Market is worth US$ 7 Billion as of now and expected to reach US$ 15 Billion by the year 2033 at a CAGR of 8% between 2023 and 2033.

With rise in geriatric population, the probability of contracting hematopoietic stem cell abounds. This factor is expected to keep the cash registers ringing for hematopoietic stem cell transplantation market in the forecast period. Plus, there is exorbitant increase in healthcare expenditure all across. There is also provision of patient analysis, cures, and prognosis.

At the same time, the fact that initial costs involved in stem cell transplantation are high can’t be ignored. This factor is expected to restrain the hematopoietic stem cell market in the forecast period.

Get your PDF Sample Report with Latest Market Info @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16462

Future Market Insights has etched these facets with future prospects in its latest market study entitled ‘Hematopoietic stem cell transplantation market’. It has its team of analysts and consultants to deploy a 360-degree approach for across macros and micros.

“With incidences of lymphoma and leukemia in an aplomb, the global hematopoietic stem cell transplantation market is expected to grow on an unstoppable note in the forecast period”, says an analyst from Future Market Insights.

Key Takeaways from Hematopoietic Stem Cell Transplantation Market

  • North America holds the largest market share due to growing incidences of myeloma, lymphoma, or leukemia all over the US. This is evident from the fact that as per the ‘Leukemia and Lymphoma Society’, over 172,910 people all across the US are suffering from myeloma, lymphoma, or leukemia.
  • The Asia-Pacific is expected to grow in hematopoietic stem cell transplantation market on the back of Japan. This is shown by the fact that the Japanese Data Center for Hematopoietic cell transplantation has mentioned that Japan witnessed maximum transplants in the Asia-Pacific.

Competitive Transplantation:

  • Ankyra is into development of Anchored Immunotherapy (a cytokine suppression-based immunotherapy). It claims to boost cytokine immunotherapy’s effectiveness.
  • OXvax is developing a DC (dendritic cell) immune-oncology vaccination platform. It does generate huge quantities of CD141+XCR1 DC subset from the induced pluripotent stem cells using an exclusive methodology (iPSC).
  • Catamaran Bio makes provisions for TAILWIND, which comes across as a patented technology package for manufacturing and engineering NK cells. NK cells are programmed using synthetic biotechnology-enabled tumor microenvironment (TME) switches with TcBuster transposon system.
  • Taiga Biotechnologies, in November 2021, did announce that the very first site based out of Croatia finished with site initiation session for TBX-2400-01 clinical trial, a Phase ½ study for evaluating early efficacy and safety of TBX-2400 in AML (acute myeloid leukemia) and myelofibrosis patients who are going through HSCT (hematopoietic stem cell transplant).
  • Lonza, in November 2022, came up with a capsule solution for administering enteric drug called ‘The Capsugel EnprotectTM’. The interesting part herein is that it is insoluble in water and does release contents solely in intestine. Capsugel EnprotectTM capsules thus do away with requirement for additional capsule sealing or coating, thereby simplifying the process of medicinal product production.
  • Regen BioPharma, in October 2022, did announce filing of provisional patent application with USPTO entitled ‘Enhancement of T Cell Homing to Tumors’ through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion’ with the ‘US Patent and Trademark Office’.
  • Takeda’s Phase 3 AURORA study, as of December 2022, does show that maribavir does have a clinically long-lasting effect on CMV (Cytomegalovirus) infection in those going through hematopoietic stem cell transplant.
  • Priothera, in May 2022, did receive clearance from the US FDA regarding investigational new drug (IND) for starting with Phase 2b/3 study with mocravimod in AML (Acute Myeloid Leukemia) patients going through Allogeneic HSCT (Hematopoietic Stem Cell Transplant).
  • The US FDA, in December 2021, did approve treatment regarding prevention of acute graft-versus-host disease (GVHD) in patients aged 2 and above who are undergoing hematopoietic stem cell transplant from single or matched HLA-mismatched unrelated donor.

What does the Report stem?

  • The research study is based on transplant type (autologous and allogeneic), by indication (acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and other non-malignant disorders), and by application (bone marrow transplant, peripheral blood stem cells transplant, and cord blood transplant).
  • With growing awareness about importance of hematopoietic stem cell transplants, the global hematopoietic stem cell transplantation market is bound to grow on a sturdy note in the forecast period.

Key Companies Profiled:

  • Pluristem Therapeutics Inc.
  • CellGenix GmbH
  • Regen Biopharma Inc.
  • Lonza Group
  • Sanofi
  • Taiga Biotechnologies, Inc.
  • Takeda Pharmaceutical Company Limited
  • Escape Therapeutics, Inc.
  • Bluebird Bio
  • Talaris Therapeutics

Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey

By Transplant Type:

  • Allogeneic
  • Autologous

By Indication:

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Other Non-Malignant Disorders

By Application:

  • Bone Marrow Transplant
  • Peripheral Blood Stem Cells Transplant
  • Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market by Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)